[go: up one dir, main page]

EP1590329A1 - N-aryl-heteroaromatische produkte,zusammensetzungen, die diese enthalten, und deren verwendung - Google Patents

N-aryl-heteroaromatische produkte,zusammensetzungen, die diese enthalten, und deren verwendung

Info

Publication number
EP1590329A1
EP1590329A1 EP04705102A EP04705102A EP1590329A1 EP 1590329 A1 EP1590329 A1 EP 1590329A1 EP 04705102 A EP04705102 A EP 04705102A EP 04705102 A EP04705102 A EP 04705102A EP 1590329 A1 EP1590329 A1 EP 1590329A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
piperazin
methanone
methyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04705102A
Other languages
English (en)
French (fr)
Inventor
Alain Le-Brun
Fabienne Thompson
Gilles Tiraboschi
Patrick Mailliet
Joseph M Salvino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0300894A external-priority patent/FR2850379B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of EP1590329A1 publication Critical patent/EP1590329A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to new chemical compounds, particularly new N-aryl-heteroaromatic products, compositions containing them, and their use as medicaments.
  • the invention relates to new N-aryl-heteroaromatic products having an anticancer activity, and in particular an activity inhibiting the polymerization of tubulin.
  • N-aryl-heteroaromatic products in question here correspond to the following general formulas (la), (Ib) or (le):
  • Van Wijngaarden et al. (US 4772604, US 4874770, EP 0241053) claim piperazine derivatives having antipsychotic properties. These patents have also been mentioned in Chem. Abs., Vol. 108 (1988), p.576, 221717q, where they were the subject of the quotation of two products, none of which is disclosed in the aforementioned patents. It is
  • Patent application WO 01/19798 claims heterocyclic compounds useful as Factor Xa inhibitors for the treatment, for example, of thrombosis, and for inhibiting the coagulation of biological samples.
  • the products described are not included in the definition of the products according to the invention, with the exception of the following compound:
  • prazosin analogs which are potential inhibitors of ⁇ 1 adrenoceptor.
  • a single prazosin analogue is a 5- (4-heteroaryl-piperazinocarbonyl) -1-phenyl-pyrazole:
  • R1, R2 are independently selected from the group consisting of aryl, heteroaryl, substituted aryl, substituted heteroaryl; R2 can also be chosen from the C5-C7 cycloalkyl group;
  • R4 is selected from the group consisting of consisting of H, (C1-C3alkyl), cyclopropyl, (C2-C3) alkylene, (C2-C3) alkynyl, 0 (C1- C3) alkyl, S- (C1-C3 ) alkyl, F, Cl, Br;
  • R5 and R6 are independently selected from the group consisting of H, (C1-C3) alkyl, oxo, halgene;
  • R7, R8, R12 are independently selected from the group consisting of H, (C1-C3) alkyl, (C1-C3) substituted alkyl;
  • R9 is (C1-C3) alkyl; in racemic form, enriched in an enantiomer, enriched in a diastereoisomer, its tautomers, its prodrugs and its pharmaceutically acceptable salts, provided that the product of formula (I) is not one of the following compounds:
  • a preferred substituent R1 may be chosen from phenyl; phenyl substituted by at least one radical chosen from halogen, (C1-C3) -alkyl, CON (R10) (R11), O-R10, S-R10, N (R10) (R11), in which R10, R11 are independently selected from H, (C1-C3) -alkyl, (C1-C3) -alkyl halogen; pyridyle; pyridyle substituted by at least one radical chosen from halogen, (C1-C3) -alkyl, CON (R10) (R11), O-R10, S-R10, N (R10) (R11), in which R10, R11 are independently chosen from H, (C1-C3) -alkyl, (C1-C3) - halogenated alkyl.
  • R1 will be phenyl substituted by halogen or (C1-C3) - alkyl, or (C1-C3) -alkoxy, or carboxamide; 2- or 3-pyridyle .; 2- or 3-pyridyle substituted by halogen or (C1-C3) -alkyle.
  • R1 is phenyl substituted by a chloro radical, one or two methoxy radicals or a carboxamide radical.
  • R1 is substituted phenyl
  • preferred combinations of substitution can be chosen from phenyl-2,3-disubstituted, phenyl-2,5-disubstituted, phenyl-3-substituted, phenyl-3,5-disubstituted, phenyl-3,4 - disubstituted, more preferably from phenyl-3-substituted, phenyl-3,5-disubstituted, phenyl-3,4-disubstituted.
  • R1 When R1 is substituted 2-pyridyle, preferred substitutions are chosen from 2-pyridyle-4- or 6-substituted or 2-pyridyle-4,6-disubstituted. When R1 is substituted 3-pyridyl, preferred substitutions are 3-pyridyl-2- or 5-substituted.
  • a preferred R2 substituent may be chosen from phenyl, 3-pyridyl, phenyl substituted by at least one radical chosen from halogen, alkyl, O-R10, S-R10, N (R10) (R11), in which R10, R11 are independently chosen from H, (C1-C3) alkyl, (C1-C3) halogenated alkyl.
  • R2 substituent is selected from unsubstituted phenyl and 3-pyridyl. Unsubstituted phenyl is more preferred.
  • R3 is H or (C1 -C3) alkyl, CF3, hydroxymethyl, amino, azetidino, pyrrolidino.
  • R3 is H or a methyl, hydroxymethyl, CF3 or amino radical.
  • R4 is H
  • products of general formula (la), (Ib) or (le) according to the invention in which L is C (O) can be prepared by coupling of a 1-aryl (heteroaryl) -pyrrole acid -2-carboxylic, or a 2-aryl (heteroaryl) -pyrazole-3-carboxylic acid, of general formula (II), in which R2 R3 and R4 are defined as above, with, respectively, a piperazine derivative of formula general (Nia) or a 1,2,3,6-tetrahydropyridine derivative (IIIb), in which R1 is defined as above, or a piperidine derivative of general formula (IIIc), in which R1 and R9 are defined such than previously according to diagram 1:
  • the coupling can be carried out using the coupling methods known to a person skilled in the art, in particular by activation of the amine (IIIa) (IIIb) or (IIIc) with trimethylaluminum under the conditions described in Organic Synthesis 59 , 49-53 (1980).
  • methyl or ethyl acids or esters of 1 -aryl (heteroaryl) -pyrrole-2-carboxylic or 2-aryl (heteroaryl) -pyrazole-3-carboxylic acids of general formula (II) can be obtained according to the methods known to those skilled in the art, in particular the ortho-earboxylation of a pyrrole or pyrazole derivative followed by the N-alkylation or N-arylation of the pyrrole or of or pyrazole according to scheme 2, in the case Pyrazoles generally give an easily separable mixture of substituted N-1 and N-2 products.
  • arylation oDG orthodirector group such as Boc, Ac, COCF 3
  • the arylation advantageously carried out by Suzuki type coupling, can be carried out by operating under the conditions described in Tetrahedron, 55, 12757 (1999).
  • the arylation can be very advantageously carried out by operating under the conditions described by Buchwald in J. Amer. Chem. Soc, 123, 7727 (2001), with an aryl halide R2-Hal, by catalysis with cuprous iodide in the presence of cesium carbonate and 1, 2-diaminocyclohexane.
  • R2 represents a phenyl radical
  • X a CH group and R4 a hydrogen atom it is possible to directly carry out the otho-carboxylation of 1-phenyl-pyrrole-2-carboxylic acid by operating according to Tetrahedron, 49, 10278 (1993).
  • the groups R3 and / or R4, different from the hydrogen atom, from 1 -aryl (heteroaryl) -pyrrole-2-carboxylic or 2-aryl (heteroaryl) -pyrazole-3-carboxylic acids of general formula (II) can also be introduced on 1-aryl (heteroaryl) -pyrrole-2-carboxylic or 2-aryl (heteroaryl) - pyrazole-3-carboxylic acids of general formula (II), in which R3 and / or R4 represent a d atom hydrogen, by any of the conventional methods known to those skilled in the art.
  • NBS NBS
  • substitutions of the bromine atom will advantageously be carried out by heating for a few minutes at 120-150 ° C. in a microwave reactor, more particularly carbon-carbon couplings of the Suzuki and Heck type or the aminations of Buchwald type.
  • substitutions of the bromine atom will advantageously be carried out by heating a few minutes at 120-150 ° C. in a microwave reactor.
  • aryl (heteroaryl) hydrazines From aryl (heteroaryl) hydrazines, it is also advantageously possible to prepare 2-aryl (heteroaryl) pyrazole-3-carboxylic esters, by operating according to J. Het. Chem., 36, 217 (1999), which will then be saponified into corresponding acids.
  • Another method of synthesis of 2-aryl (heteroaryl) pyrazole-3-carboxylic esters which is particularly advantageous in the context of the invention, uses cycloaddition reactions, followed by oxidation of the intermediate adduct obtained with chloranil, aryl (heteroaryl) hydrazones with a propiolate by operating according to Tetrahedron, 36, 887 (1980).
  • Another method of synthesis of 1-aryl (heteroaryl) pyrrole-5-carboxylic acid esters implements the reaction of an aryl (heteroaryl) amine with 2, 5-dimethoxy-tetrahydrofuran by operating according to Heterocycles, 53, 2160 (2000).
  • the aryl (heteroaryl) reaction of the piperazines can be carried out by operating under the conditions described in Biorg. Med. Chem. Lett., 11, 1375 (2001) or in Biorg. Med. Chem., 10, 3817 (2002).
  • Another method of synthesis of aryl (heteroaryl) piperazines consists in the reaction of an aryl (heteroaryl) amine with a bis ( 2-hydroxy- or 2-halo-ethyl) amine, at a temperature above 100-120 ° C according to scheme 5:
  • the 1,2,3,6-tetrahydropyridine derivatives (IIIb), in which R1, R5 and R6 are defined as above, are either commercial or prepared according to the conventional methods known to those skilled in the art.
  • the action, according to diagram 6, of an organometallic derivative of aryl (heteroaryl), such as an organomagnesium, an organolithium to an organoceric, on a derivative of piperidin-4-one whose atom nitrogen is substituted by a protective group is particularly advantageous.
  • an organometallic alkyl derivative such as an organomagnesium, an organolithium to an organoceric
  • a piperidin-4-one derivative including the nitrogen atom is substituted by a protective group
  • an aryl or heteroaryl derivative in the presence of an acid catalyst, of Lewis acid or superacid type according to Olah is particularly advantageous in the context of invention.
  • M MgCI (Br), CeCI 2 ...
  • products of general formula (la), (Ib) or (le) according to the invention in which L is CH 2 can be prepared by reduction of a compound of general formula respectively (la), (Ib ) or (le), in which L is C (O), by any of the reduction methods known to those skilled in the art, such as for example the Clemmensen or Wolff-Kishner methods, operating according to the figure 9:
  • products of general formula (la), (Ib) or (le) according to the invention in which L is CH 2 can also be prepared from the esters of the products of general formula (II), using the various methods known to those skilled in the art, according to the reaction sequences of scheme 10:
  • products of general formula (Ia), (Ib) or (Ie) according to the invention in which L is CR7R8, with R7 and / or R8 other than the hydrogen atom can also be prepared from products of general formula (II), or their esters, using the various methods known to those skilled in the art, according to the reaction sequences of scheme 11:
  • products of general formula (la), (Ib) or (le) according to the invention in which L is C (S) can be prepared by thionation of a compound of general formula respectively (la), (Ib) or (le), in which L is C (O), by any of the reduction methods known to those skilled in the art, operating according to scheme 12:
  • Figure 12 It is particularly advantageous in the context of the invention to perform thionation using the Lawesson reagent, operating according to Bull. Soc. Chim. Sc / g., 87, 293 (1978).
  • products of general formula (la), (Ib) or (le) according to the invention in which L is C (NH) can be prepared from the nitriles derived from the products of general formula (II), using the various methods known to those skilled in the art, according to the reaction sequences of scheme 13:
  • products of general formula (la) or (le) according to the invention in which L is C (NR7), with R7 equal or different from the hydrogen atom can be prepared from the products of general formula respectively (la) or (le) in which L is C (O) and / or C (S), using the various methods known to those skilled in the art, according to the reaction sequences of scheme 14:
  • products of general formula (la) according to the invention in which L is C (O), X is N, R3 is methyl, R6 and R7 are H, R1 and R2 are as defined above, can be prepared by coupling between a 1-phenyl-pyrazole-3-carboxylic acid, and a piperazine derivative according to reaction scheme 15:
  • a phenylhydrazine is condensed on an ⁇ -methyloxime of an ⁇ , ⁇ -diketoester in acid medium to produce a mixture of 5-methyl-2-phenyl-2H-pyrazole-3 acids - carboxylic and 5-methyl-1-phenyl-1H-pyrazole-3-carboxylic.
  • 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid is isolated and then engaged in an amidification reaction between the previously activated carboxylic function of pyrazole and an amine such as 4-aryl-piperazine in the medium basic to result in a product according to the invention.
  • 5-alkyl-2-phenyl-2H-pyrazole-3-carboxylic and 5-alkyl-1-phenyl-1 H-pyrazole-3-carboxylic acids can be obtained and isolated under the conditions described by Ashton, in J. Het . Chem., 30, 307 (1993).
  • products in accordance with the invention can also be prepared on solid phase, according to reaction scheme 16:
  • products of general formula (la) according to the invention in which L is C (O), X is N, R3 is different from H or methyl , R6 and R7 are H, R1 and R2 are as defined above, can be prepared from a product of general formula (la) in which R3 is a bromine atom or a bromomethyl radical or a formyl radical according to the reaction schemes 17, 18 and 19:
  • R3 alkenyl, alkynyl, aryl, heteroaryl N (R7) (R8), OR8, SR8 ....
  • reaction mixture After 3 hours of stirring at a temperature close to 20 ° C, the reaction mixture is concentrated to dryness, taken up in 5 ml of tetrahydrofuran and then slowly added to a solution of 413 mg of 1 - (3-chlorophenyl) -piperazine and 402 ⁇ L of triethylamine in 5 mL of tetrahydrofuran.
  • Example 3 presents an application of the use of the general synthetic route presented in scheme 16.
  • N-phenyl-piperazine and 5-methyl-2-phenyl-2H- acid pyrazole-3-carboxylic may be substituted by radicals as defined above, to obtain products in accordance with the invention.
  • the resins are then washed 3 times with 1 ml of DMF then alternately 4 times with 1 ml of CH2CI2 and 4 times with 1 ml of methanol then finally 2 times with 1mL of CH2CI2.
  • the resins are dried in ambient air.
  • the products were purified by LC / MS using a Waters FractionsLynx system composed of a Waters model 600 gradient pump, a Waters model 515 regeneration pump, a Waters Reagent Manager dilution pump, a car - Waters model 2700 injector, two Rheodyne LabPro valves, a Waters model 996 diode array detector, a Waters model ZMD mass spectrometer and a Gilson model 204 fraction collector.
  • the system was controlled by Waters FractionLynx software.
  • the separation was carried out alternately on two Waters Symmetry columns (Cis, 5 ⁇ M, 19x50 mm, catalog reference 186000210), one column being regenerated by a water / acetonitrile 95/5 (v / v) mixture containing 0.07% (v / v) trifluoroacetic acid, while the other column was being separated. Elution from the columns was carried out using a linear gradient of 5 to 95% acetonitrile containing 0.07% (v / v) of trifluoroacetic acid in water containing 0.07% (v / v) d trifluoroacetic acid, at a flow rate of 10 ml / min.
  • one thousandth of the effluent is separated by an LC Packing Accurate, diluted with methyl alcohol at a flow rate of 0.5 ml / min and sent to the detectors, at a rate of 75% to the array detector diodes, and the remaining 25% to the mass spectrometer.
  • the rest of the effluent (999/1000) is sent to the fraction collector where the flow is eliminated until the mass of the expected product is detected by the FractionLynx software.
  • the molecular formulas of the expected products are provided to the FractionLynx software which triggers the collection of the product when the detected mass signal corresponds to the [M + H] + ion and / or to the [M + Na] + .
  • LC / MS analyzes were carried out on a Micromass model LCT device connected to an HP 1100 device.
  • the abundance of the products was measured using an HP G1315A diode array detector over a wave range of 200-600 nm and a Sedex 65 light scattering detector.
  • Mass spectra mass spectra were acquired over a range of 180 to 800. The data were analyzed using Micromass MassLynx software.
  • the separation was carried out on a Hypersil BDS C18 column, 3 ⁇ m (50 ⁇ 4.6 mm), eluting with a linear gradient of 5 to 90% acetonitrile containing 0.05% (v / v) of trifluoroacetic acid ( TFA) in water containing 0.05% (v / v) TFA in 3.5 min at a flow rate of 1 mL / min.
  • TFA trifluoroacetic acid
  • Step 1 To a solution of 1.2 g of N, N-dimethyl-benzene-1,3-diamine, which can be obtained according to J. Org. Chem., 57, 5254 (1992), in 15 ml of n-butanol, 1.6 g of bis- (2-chloroethyl) amine hydrochloride and 2.86 g of sodium carbonate are added. After 18 hours of heating at reflux, 50 ml of dichloromethane and 40 ml of water are added, the organic phase is decanted, then washed with 40 ml of water, dried over magnesium sulphate and concentrated under reduced pressure. 2.35 g of dimethyl- (3-piperazin-1-yl-phenyl) -amine are thus obtained in the form of a viscous brown oil used as it is in the following step and the characteristics of which are as follows:
  • Step 1 To a solution of 404 mg of 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid, 360 mg of 1- (3-dimethylaminopropyl) -3-ethyl-carbodiimide hydrochloride and 270 mg of 1-hydroxybenzotriazole in 10 mL of dichloromethane, 195 mg of 0, N-dimethyl-hydroxylamine hydrochloride and 300 ⁇ L of triethylamine are added.
  • the medium is diluted with 20 ml of dichloromethane, decanted, washed with 20 ml of 1N hydrochloric acid solution and then three times with 15 ml of distilled water. After drying over magnesium sulfate, concentration under reduced pressure and purification by flash chromatography on a silica column (60; 35-70 ⁇ M), eluting with a mixture of dichloromethane and methanol (gradient from 100 to 90% of dichloromethane in volumes), 360 mg of N-methoxy-N-methyl-5-methyl-2-phenyl-2H-pyrazole-3-carboxamide are obtained, and used directly in the next step.
  • Step 2 A solution of 350 mg of N-methoxy is added to a suspension of 69 mg of lithium aluminum hydride in 3.2 ml of ethyl ether. -N-methyl-5-methyl-2-phenyl-2H-pyrazole-3-carboxamide in 1.2 ml of ethyl ether. After the temperature has risen to 5 ° C., a solution of 315 mg of sodium hydrogen sulphate in 1.1 ml of distilled water is added.
  • the organic phase is decanted, then washed twice with a 1N solution of hydrochloric acid, at a temperature in the region of 0 ° C, twice with a saturated solution of sodium hydrogen carbonate, a times with saturated sodium chloride solution, dried over magnesium sulfate and concentrated under pressure scaled down.
  • the concentrate is dissolved in 5 mL of dichloromethane and 200 mg of manganese dioxide are added.
  • the medium is concentrated under reduced pressure, taken up in 20 ml of ethyl acetate, filtered in the presence of celite, then concentrated under reduced pressure to obtain 266 mg of 5-methyl-2-phenyl-2H-pyrazole-3-carboxaldehyde in the form of a meringue, used as it is in the next step after checking by LC / MS analysis.
  • Step 3 To a solution of 39 mg of 1- (3-chlorophenyl) -piperazine in 10 ml of acetonitrile are added 55.8 mg of 5-methyl-2-phenyl-2H-pyrazole-3-carboxaldehyde, 17 ⁇ L of acetic acid and 380 mg of powdered 3 A molecular sieve. After 2 hours of stirring at a temperature close to 20 ° C, 18.9 mg of sodium cyanoborohydride are added. After 48 hours of stirring at a temperature close to 20 ° C, 200 ⁇ L of distilled water are added.
  • Step 1 To a solution of 818 mg of 5-methyl-1-H-pyrazole-3-carboxylic acid in 10 ml of DMF, are added 2.26 ml of diisopropylethylamine, 2.96 g of HATU and 1.19 mL of 1-phenylpiperazine. After 2 hours of stirring at room temperature, the reaction mixture is poured onto 100 ml of a saturated aqueous solution of sodium chloride and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 2 100 mg of product from step 1 is placed in a microwave reactor 14 mg of copper iodide, 2.0 mL of 1,4-dioxane, 38 mg of trans-1,2-diaminocyclohexane , 169 mg of cesium carbonate, 88 mg of 2-bromopyridine, 20 mg of 1-ethyl-3-methylimidazolium chloride then subjected to the microwave for 15 minutes at 140 ° C. 60 mg of copper iodide and 40 mg of 2-bromopyridine are added and again subjected to the microwave for 15 minutes at 140 ° C. The reaction mixture is poured into 50 ml of water and extracted with ethyl acetate.
  • Step 1 To a solution of 4.325 g of 1- (3-chlorophenyl) piperazine in 60 ml of toluene, 14.7 ml of 2M solution of trimethylaluminum in toluene are added at 25 ° C. then, after 10 minutes, 2.26 g of ethyl ester of 5-methyl-1-H-pyrazole-3-carboxylic acid. The reaction medium is stirred for 6 hours at 60 ° C. then poured into 100 ml of a 1 M aqueous solution of double sodium and potassium tartrate and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 1 To a solution of 1.6 g of 3- (4-phenylmethyl-piperazin-1-yl) - phenylamine, which can be obtained according to patent WO 02/090327, in 50 ml of dichloromethane, are added to the around 0 ° C, 0.93 mL of triethylamine and 0.78 mL of benzoyl chloride. After 72 hours near room temperature and addition of 50 ml of water, the organic phase is decanted, washed with twice 50 ml of water, with 50 ml of saturated sodium chloride solution and dried over magnesium sulfate then concentrated under reduced pressure.
  • Step 1 A suspension of 0.74 g of 3,5-dichloropyridine, 2.98 g of 1-terbutoxycarbonyl-piperazine, 7.33 g of cesium carbonate, 0.687 g of tris (dibenzylideneacetone) dipalladium (0), 1 , 96 g of 2-dicyclohexylphosphino- 2 '- (N, N-dimethylamino) biphenyl in 450 mL of 1,2-dimethoxyethane is brought to 90 ° C for 100 hours. The medium is concentrated under reduced pressure, then taken up in 50 ml of dichloromethane and filtered in the presence of celite.
  • Step 2 A suspension of 680 mg of 1-terbutoxycarbonyl-4- (5-chloro-3-pirydinyl) -piperazine in 1.8 ml of 5N hydrochloric acid solution is heated at 60 ° C for 3 hours. The medium is concentrated under reduced pressure, then diluted with 20 ml of dichloromethane. After adding 5 mL of normal sodium hydroxide solution, the organic phase is decanted, then washed with water, dried over magnesium sulfate and concentrated under reduced pressure to obtain 450 mg of 1- (5-chloro-3-pirydinyl) -piperazine, used as is in the next step.
  • Step 3 By proceeding in a similar manner to the synthesis of [4- (3-chlorophenyl) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3-yl) -methanone ( examplel), but by replacing 1- (3-chlorophenyl) -piperazine by 429 mg of 1- (5-chloro-3-pirydinyl) -piperazine, we obtain 286 mg of [4- (5-chloro-3- pirydinyl ) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3-yl) -methanone, in the form of a solid, the characteristics of which are the following:
  • Step 1 To a solution of 1.6 g of 3- (4-phenylmethyl-piperazin-1-yl) - phenylamine, which can be obtained according to patent WO 02/090327, in 50 mL of dichloromethane, are added in the vicinity at 0 ° C 0.93 mL of triethylamine and 0.54 mL of methyl chloroformate. After 72 hours in the vicinity of room temperature and addition of 50 ml of water, the organic phase is decanted, washed with 2 times 50 ml of water and with 50 ml of saturated sodium chloride solution, then dried over sodium sulfate. magnesium and concentrated under reduced pressure.
  • Step 3 To a solution of 1.3 g of [3- (4-phenylmethyl-piperazin-1-yl) - phenylj-methyl-amine in 65 ml of methanol under an inert atmosphere, are added 1.16 g of formate d ammonium and 53 mg of palladium on carbon at 20%. After heating in the vicinity of reflux for 4 hours, the catalyst is filtered through celite and the filtrate is concentrated under reduced pressure. 20 mL of water and 1 mL of 1N sodium hydroxide are added and then extracted with 3 times 25 mL of ethyl acetate. The combined organic phases are washed with water, dried over magnesium sulfate and then concentrated under reduced pressure.
  • Step 2 To a solution of 586 mg of 3- [4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazin-1-yl] -benzoic acid, in 25 ml of dichloromethane, 316 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 223 mg of 1-hydroxybenzotriazole hydrate (HOBT) are added.
  • EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
  • HOBT 1-hydroxybenzotriazole hydrate
  • step 2 of example E22 The procedure is similar to step 2 of example E22 starting from 150 mg of product from step 1 of example E22 and from 85 mg then 39 mg of
  • Step 1 To a solution of 2.78 g of N-phenylmethylpiperazine in 100 mL of toluene are added 2.99 g of 3-bromo-acetophenone, 317 mg of (R) - (+) - 2.2'- bis (diphenylphosphino) -1, 1'-binaphthyl, 114 mg of palladium acetate and 1.59 g of sodium tert-butoxide. After 20 hours of heating at 80 ° C., the insoluble material is filtered, 25 ml of ethyl acetate and 25 ml of water are added and the organic phase is decanted, then washed with water, dried over sulphate. magnesium and concentrated under reduced pressure.
  • Step 1 To a solution of 5.28 g of ethyl 2,4-dioxovalerate in 35 ml of DMF and 35 ml of ethanol are added 3.35 g of methylhydroxylamine hydrochloride then 9.99 g of acetate sodium trihydrate. After 2 hours of stirring at 60 ° C, the reaction mixture is filtered and the filtrate concentrated. The oil obtained is taken up in isopropyl ether and the organic phase washed with a saturated aqueous solution of sodium dihydrogen phosphate, dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 2 To a solution of 1.65 g of 1- (3-chlorophenyl) piperazine in 45 ml of toluene, 5.6 ml of 2M solution of trimethylaluminum in toluene are added at 25 ° C. then at 60 ° C, a solution of 1.21 g of dioxime A (step 1 of the present example) in 10 ml of toluene. The reaction medium is stirred for 1 hour at 75 ° C. then poured onto 100 ml of a 1 M aqueous solution of double sodium and potassium tartrate and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 3 To a solution of 110 mg of amide B in 0.6 ml of acetic acid and 0.3 ml of methylglycol, 108 mg of 2,4-difluorophenylhydrazine hydrochloride is added at 25 ° C. The reaction medium is stirred for 3.5 hours at 100 ° C. and then concentrated. After purification by flash chromatography on a silica column (40-63 ⁇ M), eluting with a mixture of heptane and ethyl acetate (70/30 by volume), 101 mg of [4- (3-chloro) are obtained.
  • Example E42 The procedure is similar to Example E42 starting from 75 mg of amide B, obtained in step 2 of Example E42, and 109 mg of 2,3,5,6-tetrafluorophenylhydrazine in the presence of 76 mg of paratoluene sulfonic acid monohydrate, for 9 hours at 100 ° C, to obtain, after purification by flash chromatography on a silica column (40-63 ⁇ M), eluting with a mixture of heptane and ethyl acetate (80/20 by volume), 14 mg of [4- (3-chloro-phenyl) -piperazin-1-yl] - [5-methyl-2- (2,3,5,6-tetrafluorophenyl) - 2H-pyrazol-3-yl] -methanone, in the form of a yellow solid, the characteristics of which are the following:
  • Example E45 The procedure is similar to Example E45 starting from 106 mg of amide B, obtained in step 2 of Example E42, and from 60 mg of 2,5-dimethylphenylhydrazine hydrochloride to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of heptane and ethyl acetate (80/20 by volume), 46 mg of [4- (3-chlorophenyl) -piperazine -1-yl] - [2- (2,5-dimethyl-phenyl) -5-methyl-2H-pyrazol-3-yl] - methanone, in the form of a white solid, the characteristics of which are the following:
  • Example E45 from 106 mg of amide B, obtained in step 2 of Example E42, and from 74 mg of cyclohexylhydrazine hydrochloride, for 6 hours at 100 ° C., for obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of heptane and ethyl acetate (80/20 by volume), 70 mg of [4- (3-chloro -phenyl) -piperazin-1-yl] - (2-cyclohexyl-5-methyl-2H- pyrazol-3-yl) -methanone, in the form of a white solid, the characteristics of which are the following:
  • Step 1 To a solution of 3.12 g of ethyl ester of 5-hydroxy-1H-pyrazole-3-carboxylic acid, which can be prepared according to Chem. Pharm. Bull. 31 (4) 1228 (1983) using toluene instead of benzene, in 40 ml of dichloromethane and 3.1 ml of triethylamine, cooled to 0 ° C., a solution of 4.58 g of N-terbutoxycarbonyl anhydride (Boc 2 0) in 40 ml of dichloromethane. The reaction medium is stirred for 3 hours at room temperature, then washed with a saturated aqueous solution of sodium dihydrogen phosphate.
  • Boc 2 0 N-terbutoxycarbonyl anhydride
  • Step 2 To a solution of 796 mg of step 1 of the present example and 1.11 g of cesium carbonate in 15 ml of DMF at -5 ° C., a solution of 0.37 ml of bromide is added. benzyl in 3 mL of DMF. The reaction medium is stirred for 3 hours at 0 ° C., then poured onto a saturated aqueous solution of sodium dihydrogen phosphate and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 5 In a microwave reactor, place 100 mg of product from step 4 of the present example, 10 mg of copper iodide, 2.0 mL of 1,4-dioxane, 30 ⁇ L of trans -1, 2-diaminocyclohexane, 115 mg of cesium carbonate, 37 ⁇ L of 2-bromopyridine, 30 ⁇ L of 1-hexyl-3-methylimidazolium pentafluorophosphate, then subjected to the microwave for 15 minutes at 140 ° C.
  • Step 1 The synthesis of the ethyl ester of 5-bromo-2-phenyl-2H-pyrazole-3-carboxylic acid, according to Tetrahedron Lett., 40, 2605 (1999), from 1.64 g d acetic acid (phenyl-hydrazono) and 3.56 g of N-bromosuccinimide in 40 ml of DMF then addition of 5.1 ml of ethyl propiolate and 1.4 ml of triethylamine gives after 2 successive purifications by flash chromatography on a silica column (40-63 ⁇ M), eluting respectively with a mixture of heptane and ethyl acetate (90/10 by volume) and for the fractions still impure with another mixture of cyclohexane and acetone (95/5 in volumes):
  • Step 2 The procedure in step 2 of Example E42 is carried out similarly from 192 mg of 5-bromo-2-phenyl-2H-pyrazole-3-carboxylic acid ethyl ester, containing 10 to 20% ethyl ester of 5-bromo-2- (4-bromo ⁇ phenyl) -2H-pyrazole-3-carboxylic acid, and 256 mg of 1- (3-chlorophenyl) piperazine to obtain, after purification by flash chromatography on a silica column (40-63 ⁇ M), eluting with a mixture of cyclohexane and ethyl acetate (80/20 by volume):
  • Step 2 In a 500 ml three-necked flask under an argon atmosphere, 14.22 g of ethyl ester of 3-bromomethyl-1-phenyl-1-H-pyrazole-5-carboxylic acid, dissolved as in the previous step, in 170 mL of dimethylformamide, then 7.95 g of sodium benzoate are added and the mixture is heated at 50 ° C for 3 hours. After cooling and concentration under reduced pressure, the residue is poured into 200 ml of water and then extracted with 3 times 100 ml of ethyl acetate. The combined organic phases are washed with a saturated aqueous solution of ammonium chloride, dried over magnesium sulfate and concentrated under reduced pressure. 15.5 g of ethyl ester of 3-benzoyloxymethyl-1-phenyl-1-H-pyrazole-5-carboxylic acid are thus obtained, in the form of a beige powder used as it is in the following step.
  • Step 3 In a 500 ml three-necked flask under an argon atmosphere, 2.1 g of (3,5-dimethoxy-phenyl) piperazine are dissolved in 8 ml of dry toluene at 30 ° C., then 4 are added dropwise. , 5 mL of a 2M solution in trimethylaluminum toluene and the mixture is stirred for 30 minutes. After cooling to 20 ° C., 1.06 g of ethyl ester of 3-benzoyloxymethyl-1-phenyl-1-H-pyrazole-5-carboxylic acid obtained in the preceding step is added in solution in 20 ml of toluene.
  • reaction medium After 7 hours of heating at 60 ° C., the reaction medium is poured into 70 ml of a 1 M aqueous solution of mixed sodium and potassium tartrate, then extracted with 3 times 50 mL of ethyl acetate. The combined organic phases are washed with 50 mL of 1 M aqueous solution of mixed sodium and potassium tartrate, dried over magnesium sulfate and concentrated under reduced pressure.
  • the orange oil obtained is purified by flash chromatography on a silica column (60; 35-70 ⁇ M), eluting with a mixture of dichloromethane and methanol (99.5 / 0.5 by volume), thus obtaining 0 , 8 g of [4- (3,5-dimethoxyphenyl) -piperazin-1-yl] - (5-hydroxymethyl-2-phenyl-2H-pyrazol-3-yl) - methanone, in the form of a meringue light beige, the characteristics of which are as follows:
  • reaction mixture is stirred and brought to reflux for 16 hours. After returning to 20 ° C. , the reaction mixture is diluted with water (20 ml) then extracted with ethyl acetate (2 x 30 ml. The organic extracts are combined, dried over magnesium sulphate, filtered and evaporated The compound obtained is purified by chromatography on silica gel (AIT cartridge, Ref. FC-25 Si-BP-SUP, 20-40 ⁇ m, eluent dichloromethane, flow rate of 20 mL / min).
  • Step 2 In a 10 ml flask, place a solution of 253 mg of tert-butyl ester of 4- (3-difluoromethoxy-phenyl) -piperazine-1-carboxylic acid in a mixture of 1016 ⁇ L of dioxane and 963 ⁇ L of hydrochloric acid. The reaction mixture is stirred at 20 ° C for 48 hours. The solid formed is filtered, washed with 10 ml of di-isopropyl ether and dried under reduced pressure. 189 mg of 1- (3-difluoromethoxy-phenyl) -piperazine hydrochloride are thus isolated, which is used without purification for the following step.
  • Step 3 In a 50 ml three-necked flask, inert with argon, a solution of 144.4 mg of 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid is placed, which can be obtained according to J Het Chem., 30, 307 (1993), in 11 mL of dichloromethane, then 189 mg of 1- (3-difluoromethoxy-phenyl) -piperazine hydrochloride, 106.1 mg of 1-hydroxybenzo-triazole, 150 are successively added. , 6 mg of 1- (3-dimethyl aminopropyl) -3- ethylcarbodiimide hydrochloride then 331 ⁇ L of triethylamine (331 ⁇ l).
  • the reaction mixture is stirred at 20 ° C for 48 hours then diluted with dichloromethane (20 mL) and water (20 mL), decanted and extracted (30 mL of dichloromethane). The organic extracts are combined, dried over magnesium sulfate, filtered and evaporated under reduced pressure.
  • the compound obtained is purified by chromatography on silica gel (AIT cartridge, Ref. FC 25-Si- HP, 15-35 ⁇ m, eluent cyclohexane / ethyl acetate, 80/20 to 60/40 in 60 minutes, flow rate of 7 ml / min). The fractions containing the expected compound are combined and then evaporated under reduced pressure.
  • Step 2 The procedure in step 1 of Example E22 is carried out similarly from 114 mg of the product from Step 1 of the present example and 145 mg of 1- (3-chlorophenyl) piperazine, for obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of ethyl acetate and triethylamine (90/10 by volume), 21 mg of [4- (3-chloro - phenyl) -piperazin-1-yl] - [5- (2-methyl-imidazol-1-ylmethyl) -2-phenyl-2H-pyrazol- 3-yl] -methanone, in the form of a yellow oil, the features are:
  • Step 2 The procedure is similar to step 2 of Example E75, starting from 79 mg of the product from Step 1 of the present example and 170 mg of 1- (3-chlorophenyl) piperazine, for obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a
  • Step 1 By operating as in step 1 of Example 73, but collecting the eluted fractions between 150 and 550 ml, 9 g of ethyl ester are obtained. 3-dibromomethyl-1-phenyl-1-H-pyrazole-5-carboxylic acid, in the form of an orange oil used as it is in the next step.
  • Step 2 To a solution of 195 mg of 1- (3,5-dimethoxyphenyl) piperazine in 2 ml of toluene are added, at 25 ° C, 0.52 ml of 2M solution of trimethylaluminum in toluene then, at 60 ° C, a solution of 162 mg of product from step 1 of the example present in 4 ml of toluene.
  • the reaction medium is stirred for 2.5 hours at 65 ° C then 1.5 hours at 80 ° C then poured onto 10 ml of a 1 M aqueous solution of double sodium and potassium tartrate and extracted with acetate. 'ethyl.
  • the organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 2 The procedure is similar to step 2 of Example E75, starting with 52 mg of the product from Step 1 of the present example and 122 mg of 1- (3-chlorophenyl) piperazine, for 1.5 hours at 60 ° C., to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of dichloromethane and ethyl acetate (95/5 by volume), 54 mg of (5-benzyloxymethyl-2-phenyl-2H-pyrazol-3-yl) - [4- (3-chloro-phenyl) -piperazin-1-yl] -methanone, in the form of a pale yellow oil, the features are:
  • reaction 1 38.87 ⁇ L of 2-bromopropane
  • analysis by thin layer chromatography shows that reaction 1 is complete.
  • the contents of reactors 1 to 4 are transferred into 4 glass tubes 36 x 100 each reactor tube being rinsed with ethyl acetate (15 ml) and water (15 ml) and then transferred to the platform liquid liquid extraction.
  • the following protocol is applied to the three reaction mixtures: decantation of the two phases, separation of the heavy and light extracts, then extraction of the heavy phases with ethyl acetate (2 ⁇ 10 ml), reunification of the organic extracts.
  • the compounds are isolated and purified by chromatography on silica gel (pre-filled cartridge, diameter 26 mm, height 135 mm, Si0 2 15-40 ⁇ m), eluting with mixtures of cyclohexane and ethyl acetate (E84: 90-10 in volumes at 10 mL / min; E105: 80-20 in volumes at 10 mL / min, E108: 80- 20 in volumes at 10 mL / min; E109: 75-25 in volumes at 10 mL / min).
  • Example E66 from 150 mg of the product of Example E82 and 57.5 mg of thienyl-3-boronic acid, by reaction under microwave for 3 minutes at 140 ° C., to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of heptane and ethyl acetate (70/30 by volume), 126 mg of [4-3,5- dimethoxy-phenyl) -piperazin-1-yl] - [2-phenyl-5- (thiophen-3-yl) -2H-pyrazol-3-yl] -ethanone, in the form of an ocher solid whose characteristics are the following:
  • Example E66 [4- (3,5-Dimethoxy-phenyl) -piperazin-1-yl] - ⁇ 5- [E-2- (4-fluoro-phenyl) -vinyl] -2- phenyl-2H-pyrazol-3-yl ⁇ -methanone
  • the procedure is similar to Example E66 starting with 150 mg of the product of Example E82 and 75 mg of trans-2- (4-fluorophenyl) vinylboronic acid, by reaction under microwave for 3 minutes at 140 ° C., to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of heptane and ethyl acetate (70/03 by volume), 118 g of [4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - ⁇ 5- [E-2- (4-fluoro-phenyl) - vinyl] -2-phenyl-2H-pyr
  • Example E66 From 150 mg of the product of Example E82 and 86 mg of 4- (trifluoromethyl) phenylboronic acid, by reaction under microwave for 3 minutes at 140 ° C.
  • Example E66 The procedure is similar to Example E66 from 153 mg of the product of Example E82 and 105 mg of 1- (t-butoxycarbonyl) pyrrole-2-boronic acid, by reaction under microwave for 3 minutes at 140 ° C., to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of heptane and ethyl acetate (70/30 by volume), 68 mg of [ 4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - [2-phenyl-5- (1H-pyrrol-2- yl) -2H-pyrazol-3-yl] -methanone, in the form of a pale yellow solid whose characteristics are the following:
  • Step 1 To 300 mg of product from step 1 of Example E70 in 4 mL of ethanol and 120 ⁇ L of pyridine, 94 mg of hydroxylamine hydrochloride are added at 0 ° C. The reaction mixture is stirred for 1 hour at room temperature, poured onto 10 ml of saturated aqueous sodium dihydrogen phosphate solution and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Example E93 (5-Benzylamino-2-phenyl-2H-pyrazol-3-yl) - [4- (3,5-dimethoxy-phenyl) - piperazin-1-yl] -methanone
  • the procedure is similar to Example E93, from 100 mg of the product of Example E82, 21 mg of tris (dibenzylideneacetone) dipalladium (0), 64 mg of 2- (ditert-butylphosphino) biphenyl in 0.60 ml of DME, to which are added 116 ⁇ L of benzylamine, 30.5 mg sodium tert-butoxide and 0.40 mL DME.
  • reaction mixture is subjected to the microwave field for 5 minutes at 90 ° C, supplemented with 10 mg of tris (dibenzylidene acetone) dipalladium (O) and again subjected to the microwave field for 3 minutes at 100 ° C.
  • 30 mg of (5-benzylamino-2-phenyl-2H-pyrazol-3-yl) is obtained - [4- (3 , 5-dimethoxy-phenyl) -piperazin-1-yl] -methanone, in the form of a white powder, the characteristics of which are the following:
  • Step 1 The procedure is similar to Example E98 from 100 mg of the product of Example E82 and 142 ⁇ L of benzophenone imine.
  • the reaction mixture is subjected to the microwave for 12 minutes at 80 ° C., supplemented with 10 mg of tris (dibenzylideneacetone) dipalladium (0) and 100 ⁇ L of DME and again subjected to the microwave field for 2 minutes at 90 ° C.
  • Stage 2 In a microwave reactor, at 66 mg of the product of stage 1 of the example present in 2.5 ml of methanol, 131 mg of ammonium formate and 60 mg of palladium on carbon are added to 10%. The reaction mixture is subjected to the microwave for 3 minutes at 100 ° C., filtered, concentrated under reduced pressure, then purified by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of dichloromethane and ethyl acetate (70/30 by volume), to give 29 mg of (5-amino-2-phenyl-2H-pyrazol-3-yl) - [4- (3,5-dimethoxy-phenyl) -piperazin- 1 - yl] -methanone, in the form of a pale yellow solid whose characteristics are the following:
  • Step 1 To a solution of 68 mg of phenol in 1.5 ml of acetone is added 0.58 ml of 1M sodium hydroxide. The reaction mixture is stirred for 45 minutes at room temperature, then treated with a solution of 150 mg of ethyl ester of 5-bromomethyl-2-phenyl-2-H-pyrazole-3-carboxylic acid, obtained with step 1 of Example E73, in 1.5 ml of acetone. The reaction mixture is stirred for 5 hours at room temperature, then poured into 20 ml of saturated aqueous sodium dihydrogen phosphate solution and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • step 2 of example E75 The procedure in step 2 of example E75 is carried out starting from 73 mg of the product from step 1 of the example present and 179 mg of 1- (3-chlorophenyl) piperazine, for 3 hours at 60 ° C, to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of dichloromethane and ethyl acetate (95/5 by volume), 78 mg of [4- (3-chloro-phenyl) -piperazin-1-yl] - (5-phenoxymethyl-2-phenyl-2H-pyrazol-3-yl) -methanone, in the form of a white solid, the characteristics of which are the following:
  • Step 1 To a solution of 66 ⁇ L of thiophenol in 2 ml of THF, cooled to 5 ° C., is added a solution of 73 mg of potassium tert-butoxide in 1 ml of THF. The reaction mixture is stirred for 10 minutes at 10 ° C., then treated with a solution of 200 mg of ethyl acid ester
  • Step 2 To a solution of 8 g of tert-butyl ester of 4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazine-1-carboxylic acid in 50 ml of dichloromethane , 27 mL of a 4N hydrochloric acid solution in dioxane are added dropwise. After 20 hours of reaction and concentration under reduced pressure, the residue is taken up in a solution of sodium hydroxide N to pH10, extracted with 50 ml of ethyl acetate, dried over sodium sulfate and concentrated under reduced pressure .
  • Step 3 To a solution of 200 mg of (5-methyl-2-phenyl-2H-pyrazol-3-yl) - (piperazin-1-yl) -methanone in 6 ml of toluene, 121 mg of 3- bromothiophene, 46 mg of (R) - (+) - 2,2'-bis (diphenylphosphino) -1, 1'- binaphthyl, 17 mg of palladium acetate and 71 mg of sodium tert-butoxide.
  • the insoluble material is filtered, 50 ml of ethyl acetate and the organic phase is decanted, then washed with 3 times 10 ml of water, dried over magnesium sulphate and concentrated under reduced pressure.
  • Example E108 This example is described with example E84
  • Step 1 To a solution of 4.4 g of ethyl ester of 3- [4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazin-1-yl] -benzoic acid , described in Example E28, in 75 ml of distilled water and 150 ml of methanol, 763 mg of potassium hydroxide in pellets are added. After 20 hours at room temperature, the reaction mixture is concentrated under reduced pressure and the residue is acidified with 5N hydrochloric acid to pH 5.
  • Step 2 To a solution of 390.5 mg of 3- [4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazin-1-yl] -benzoic acid in 17 mL of dichloro - methane, are added 211 mg of 1 - (3-dimethylaminopropyl) - 3-ethylcarbodiimide hydrochloride (EDCI), 148 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 175 mg of tert-butyl acid ester (2-amino-ethyl) -methyl- carbamic. The reaction mixture is stirred for 72 hours at room temperature.
  • Step 3 To a solution of 440 mg of methyl- (2- ⁇ 3- [4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazin) tert-butyl ester of methyl acid -1-yl] - benzoylamino ⁇ -ethyl) -carbamic acid in 1 ml of dioxane, 1 ml of a 4N hydrochloric acid solution in dioxane are added dropwise. 440 mg of N- (2-methylamino-ethyl) -3- [4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) are thus obtained, after 20 hours of reaction and concentration under reduced pressure.
  • Step 1 To a solution of 1.4 g of 5-hydroxy-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid ethyl ester, which is obtained as a secondary product in the synthesis of the example 71, in 35 ml of tetrahydrofuran, are added in the vicinity of 0 ° C 455 mg of sodium hydride at 60% in petroleum jelly oil and 1.15 g of chloro-methoxy-methane. After 20 hours of reaction at room temperature, 50 mL of water and 50 mL ethyl acetate are added and the organic phase is decanted, washed with water, dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 2 To a solution of 1.1 g of the ethyl ester of 5-methoxy-methoxymethyl-2-phenyl-2H-pyrazole-3-carboxylic acid in 12 ml of ethanol are added 6 ml of water and 250 mg of potassium hydroxide. After
  • Step 1 To a solution of 3.1 g of tert-butyl ester of 4- (3-carboxy-phenyl) -piperazine-1-carboxylic acid, which can be obtained according to patent GB 2327609, in 15 mL of dioxane is added at 0 ° C, a solution of 0.86 mL of oxalyl chloride. To this reaction mixture is added a drop of dimethylformamide. After 2 hours of stirring at a temperature close to 20 ° C., the reaction mixture is added dropwise to 50 ml of a 40% aqueous methylamine solution.
  • Step 2 To a solution of 1.5 g of tert-butyl ester of 4- (3-methylcarbamoyl-phenyl) -piperazine-1-carboxylic acid in 5.8 ml of dioxane, are added dropwise 5.9 mL of a 4N hydrochloric acid solution in dioxane.
  • Step 3 By proceeding in a similar manner to the synthesis of [4- (3-chlorophenyl) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3-yl) -methanone ( example 1), but by replacing 1- (3-chloro-phenyl) -piperazine by 584 mg of N-methyl-3- (piperazin-1-yl) -benzamide, one obtains 450 mg of N-methyl-3- [4- (5-methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazin-1-yl] - benzamide, in the form of a beige solid, the characteristics of which are the following:
  • Step 1 To a solution of 150 mg of ethyl ester of 5-bromomethyl-2-phenyl-2-H-pyrazole-3-carboxylic acid, obtained in step 1 of Example E73, in 2 mL of DMSO at room temperature, 32 mg of sodium azide are added. The reaction mixture is stirred for 2 hours at room temperature, then 1 hour at 50 ° C. and finally poured into 50 ml of water and extracted with ethyl acetate. The organic phase is dried over magnesium sulphate and concentrated under reduced pressure to give 135 mg of ethyl ester of 5-azidomethyl-2-phenyl-2H-pyrazole-3- acid. carboxylic, in the form of a pale yellow oil, the characteristics of which are as follows:
  • Step 2 We proceed in a similar way to step 2 of example E94, starting from 135 mg of the product of step 1 of example present and 221 mg of 1- (3,5-dimethoxyphenyl) piperazine for 6 hours at 60 ° C, to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of dichloromethane and ethyl acetate (95/5 by volume), 129 mg of (5-azidomethyl-2-phenyl-2H-pyrazol-3-yl) - [4- (3,5-dimethoxy-phenyl) -piperazin-1 -yl] -methanone, in the form of a white solid, the characteristics of which are the following:
  • Step 3 To a solution of 129 mg of the product of step 2 of the example present in 3 mL of THF at room temperature, 90 mg of triphenylphosphine is added. The reaction mixture is stirred for 6 hours at room temperature, then added with 0.6 ml of water, stirred for
  • Step 1 The procedure is similar to step 1 of Example E80, starting from 34 ⁇ L of 2-fluoroethanol and 150 mg of ethyl acid ester.
  • Step 2 The procedure is similar to step 2 of Example E80, starting with 66 mg of the product from Step 1 of the present example and 151 mg of 1- (3,5- dimethoxyphenyl) piperazine for 4 hours at 60 ° C, to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M), eluting with a mixture of dichloromethane and ethyl acetate (60/40 by volume) , 86 mg of [4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - [5- (2-fluoroethoxymethyl) -2-phenyl-2H-pyrazol-3-yl] -methanone, in the form of a pale yellow oil, the characteristics of which are as follows:
  • Example E124 The procedure is similar to Example E124, starting from 0.595 ml of a 1N solution of ethylmagnesium bromide in THF and 100 mg of 5- [4- (3,5-dimethoxy-phenyl) -piperazine-1 - carbonyl] -1-phenyl-1 H-pyrazole-3-carboxaldehyde, obtained in example E100, in 1.5 ml of THF, to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M) , eluting with a mixture of dichloromethane and ethyl acetate (60/40 by volume), 36 mg of [4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - [5- (1- hydroxy propyl) -2-phenyl-2H-pyrazol-3-yl] -methanone, in the form of a colorless resin the characteristics of which are the following: LC / MS
  • reaction mixture is then neutralized with a saturated solution of sodium bicarbonate, extracted with three times 50 ml of dichloromethane, washed with 50 ml of water. After drying over magnesium sulfate and concentration under reduced pressure, then purification by flash chromatography on a column of silica (60; 35-70 ⁇ M), eluting with a mixture of dichloromethane and methanol (90-10 by volume), obtains 20 mg of 3-hydroxy-N- ⁇ 3- [4- (5- methyl-2-phenyl-2H-pyrazole-3-carbonyl) -piperazin-1-yl] -phenyl ⁇ - propionamide, in the form of an amorphous beige solid with the following characteristics:
  • Example E124 The procedure is similar to Example E124, starting from 0.36 ml of a 1N solution of phenylmagnesium bromide in THF and 100 mg of 5- [4- (3,5-dimethoxy-phenyl) -piperazine-1 -carbonyl] -1 -phenyl-1 H-pyrazole-3-carboxaldehyde, obtained in example E100, in 1.5 ml of THF, to obtain, after purification by flash chromatography on a silica column (30-60 ⁇ M ), eluting with a mixture of dichloromethane and ethyl acetate (60/40 by volume), 81 mg of [4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - [5- (hydroxy - phenyl-methyl) -2-phenyl-2H-pyrazol-3-yl] -methanone, in the form of a white solid, the characteristics of which are the following: LC
  • Step 2 By proceeding in a similar manner to the synthesis of [4- (3-chlorophenyl) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3-yl) -methanone, but by replacing 1 - (3-chloro-phenyl) -piperazine by 265 mg of [3- (piperazin-1-yl) -phenyl] -methanol hydrochloride, one obtains 250 mg of [4- (3-hydroxymethyl- phenyl) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3-yl) - methanone, in the form of a beige meringue, the characteristics of which are as follows:
  • Step 1 4- (3-Difluoromethoxy-phenyl) -piperazine-1-carboxylic acid tert-butylate
  • Step 2 1- (3-Difluoromethoxy-phenyl) -piperazine hydrochloride
  • a solution of 4- (3-Difluoromethoxy-phenyl) -piperazine-1-carboxylic acid (253 mg, 3.8 mmol) in a mixture of dioxane (1016 ⁇ l) is placed in a 10 ml flask. and hydrochloric acid (963 ⁇ l).
  • the reaction mixture is stirred at 20 ° C for 48 hours.
  • the solid formed is filtered, washed (di-isopropyl ether, 10 ml) and dried under reduced pressure.
  • Step 3 [4- (3-Difluoromethoxy-phenyl) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3-yl) -methanone hydrochloride
  • a solution of 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid, which can be obtained according to J. Het Chem., 30, is placed in a 50 ml three-necked flask, inert with argon.
  • the organic extracts are combined, dried over magnesium sulfate, filtered and evaporated under reduced pressure.
  • the compound obtained is purified by chromatography on silica gel (AIT cartridge, Ref. FC 25-Si-HP, 15-35 ⁇ m, eluent cyclohexane / ethyl acetate, 80/20 to 60/40 in 60 minutes, flow rate of 7 ml / min).
  • the fractions containing the expected compound are combined and then evaporated under reduced pressure.
  • reaction medium is stirred for 30 minutes at -78 ° C and then treated with a solution of 87 mg of N-fluorobenzenesulfonimide in 1 ml of THF.
  • the reaction medium is stirred for 1.5 hours at -78 ° C. and then 16 hours at room temperature, poured onto 50 ml of saturated aqueous sodium dihydrogen phosphate solution and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure.
  • Step 1 3-Benzyloxy-5-bromo-pyridine
  • a solution of 5-bromopyridine-3-ol (1 g, 5.74 mmol) is placed in dimethylformamide (15 ml) then, at 20 ° C, potassium carbonate (794.3 mg, 5.74 mmol) and benzyl bromide (687 ⁇ l, 5.74 mmol) are added.
  • the reaction mixture is stirred at 20 ° C for 16 hours then diluted with ethyl acetate (150 ml) and water (150 ml); After decantation, extraction is carried out with 2 portions of ethyl acetate (50ml).
  • Step 2 4- (5-benzyloxy-pyridin-3-yl) -piperazine-1-carboxylic acid tert-butyl ester
  • Step 3 1- (5-benzyloxy-pyridin-3-yl) -piperazine hydrochloride
  • a solution of the terbutyl ester of 4- (5-benzyloxy-pyridin-3 acid) -yl) -piperazine-1 -carboxylic 280.1 mg, 0.758 ⁇ mol
  • dioxane 1 ml
  • hydrochloric acid 948 ⁇ l
  • the reaction mixture is stirred at 22 ° C for 16 hours.
  • the yellow solid formed is filtered, rinsed with di-isopropyl ether (15 ml) and then dried under reduced pressure.
  • the 1- (5-benzyloxy-pyridin-3-yl) -piperazine hydrochloride, 280 mg, 98%) is isolated, which is used as in the following step.
  • Step 4 [4- (5-Benzyloxy-pyridin-3-yl) -piperazin-1 -yl] - (5-methyl-2-phenyl-2H- pyrazol-3-yl) -methanone
  • a solution of 5-methyl-2-phenyl-2H-pyrazole-3-carboxylic acid is placed, which can be obtained according to J.
  • the reaction mixture is stirred at 20 ° C for 16 hours then diluted with dichloromethane (20 ml) and water (10 ml), decanted and extracted (30 ml of dichloromethane). The organic extracts are combined, dried over magnesium sulfate, filtered and evaporated under reduced pressure.
  • the compound obtained is purified by chromatography on silica gel (AIT cartridge, Ref. FC 25-Si- HP, 15-35 ⁇ m, eluent 100% dichloromethane to dichloromethane / methanol 90/10 in 60 minutes, flow rate of 7 ml / min) .
  • Step 4 [4- (5-Hydroxy-pyridin-3-yl) -piperazin-1 -yl] - (5-methyl-2-phenyl-2H- pyrazol-3-yl) -methanone
  • a solution of [4- (5-Benzyloxy-pyridin-3-yl) -piperazin-1-yl] - (5-methyl-2-phenyl-2H-pyrazol-3- yl) -methanone (268 mg; 591 ⁇ mol) in ethanol (22.5 ml) then add the ammonium formate (231.1 mg, 3.664 mmol) and the palladium on carbon (94.3 mg, 88.6 ⁇ mol) and wear the reaction mixture at 80 ° C for 3.5 hours.
  • the catalyst After returning to 20 ° C., the catalyst is removed by filtration on celite and then the filtrate is evaporated under reduced pressure.
  • the compound obtained is purified by chromatography on silica gel (26 mm diameter cartridge, 135 mm height, 20 g of silica 15-40 ⁇ m, eluent from 100% dichloromethane to 80/20 dichloromethane / methanol in 60 minutes, flow rate of 10 ml / min).
  • a product in accordance with the invention may be used for the manufacture of a medicament useful for treating a pathological condition, in particular cancer.
  • the present invention also relates to therapeutic compositions containing a compound according to the invention, in combination with a pharmaceutically acceptable excipient according to the mode of administration chosen.
  • the pharmaceutical composition can be in solid, liquid or liposome form.
  • solid compositions mention may be made of powders, capsules, tablets.
  • oral forms it is also possible to include the solid forms protected from the acidic environment of the stomach.
  • the supports used for the solid forms consist in particular of mineral supports such as phosphates, carbonates or organic supports such as lactose, celluloses, starch or polymers.
  • Liquid forms are made up of suspension or dispersion solutions. They contain as dispersive support either water or an organic solvent (ethanol, NMP or others) or mixtures of surfactants and solvents or complexing agents and solvents.
  • the liquid forms will preferably be injectable and, therefore, will have an acceptable formulation for such use.
  • Acceptable routes of injection include the intravenous, intraperitoneal, intramuscular, and subcutaneous routes, the intravenous route being preferred.
  • the administered dose of the compounds of the invention will be adapted by the practitioner according to the route of administration of the patient and the condition of the latter.
  • the compounds of the present invention can be administered alone or in admixture with other anticancer agents.
  • anticancer agents we can cite:
  • alkylating agents and in particular cyclophosphamide, melphalan, ifosfamide, chlorambucil, busulfan, thiotepa, prednimustine, carmustine, lomustine, semustine, steptozotocine, decarbazine, temozolomide, procarbazine and l 'hexamethylmelamine
  • platinum derivatives such as cisplatin, carboplatin or oxaliplatin • antibiotic agents such as bleomycin, mitomycin, dactinomycin
  • antimicrotubule agents such as vinblastine, vincristine, vindesine, vinorelbine, taxoides (paclitaxel and docetaxel)
  • anthracyclines such as doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone, losoxantrone
  • fluoropyrimidines such as 5-fluorouracil, UFT, floxuridine
  • cytidine analogues such as 5-azacytidine, cytarabine, gemcitabine, 6-mercaptomurine, 6-thioguanine
  • adenosine analogs such as pentostatin, cytarabine or fludarabine phosphate
  • methotrexate and folinic acid • enzymes and various compounds such as L-asparaginase, hydroxyurea, trans-retinoic acid, suramin, dexrazoxane, amifostine, herceptin as well as estrogenic hormones , androgenic
  • anti-vascular agents such as combretastatin or colchicine derivatives and their prodrugs.
  • a product in accordance with the invention may be useful for inhibiting the polymerization of tubulin in vitro. Evaluation of the inhibition of tubulin polymerization
  • Tubulin is purified from pig brains according to published methods (Shelanski et al., 1973, Proc. Natl. Acad. Sci.USA, 70, 765-768. Weinberger et al., 1975, Proc. Natl. Acad Sci. USA, 72, 1858-1862). Briefly, the brains are ground and centrifuged in an extraction buffer. The tubulin, contained in the supernatant of the extract undergoes two successive cycles of polymerization at 37 ° C and depolymerization at 4 ° C, before being separated from MAPs (Microtubule Associated Proteins) by chromatography on a P11 phosphocellulose column (Whatman) . Tubulin, thus isolated is more than 95% pure.
  • MAPs Microtubule Associated Proteins
  • RB / 2 30% glycerol the composition of which is MES-NaOH [2- (N-morpholino) -ethanesulfonic acid] 50 mM, pH 6.8; 0.25 mM MgCl 2 ; 0.5 mM EGTA; glycerol 30% (v / v), GTP (guanosine-5'-tri-phosphate) 0.2 mM.
  • tubulin in microtubules is followed by turbidimetry as follows: the tubulin is adjusted to a concentration of 10 ⁇ M (1 mg / ml) in the RB / 2 30% glycerol buffer to which 1 mM GTP and 6 mM MgCl 2 are added .
  • the polymerization is triggered by an increase in temperature from 6 ° C to 37 ° C in a cell with a 1 cm optical path, placed in a UVIKON 931 spectrophotometer (Kontron) equipped with a thermostatically controlled cell holder.
  • the increase in the turbidity of the solution is followed at 350 nm.
  • the products are dissolved in 10 mM in DMSO and added at variable concentrations (0.5 to 10 ⁇ M) to the tubulin solution before polymerization.
  • the IC50 is defined as the concentration of product which inhibits the rate of polymerization by 50%.
  • a product whose IC 50 is less than or equal to 25 ⁇ M is considered to be very active.
  • a product in accordance with the invention may be useful for inhibiting the proliferation of tumor cells in vitro.
  • HCT116 cells The proliferation of HCT116 cells is evaluated by measuring the incorporation of [ 14 C] -thymidine as follows.
  • HCT116 cells (from ATCC) are cultured in a DMEM medium (Gibco) which contains 10% fetal calf serum and antibiotics (penicillin 1%, streptomycin 1%).
  • DMEM medium Gibco
  • antibiotics penicillin 1%, streptomycin 1%
  • the cells are seeded in 96-well cytostar microplates (Amersham), at a rate of 5000 cells per well.
  • [ 14 C] -thymidine 0.1 ⁇ Ci / well
  • Variable concentrations of products are used up to 10 ⁇ M; the DMSO (solvent used to dissolve the products) must not exceed 0.5% in the medium.
  • IC 5 o is defined as the concentration of product which reduces by 50% the radioactivity compared to an untreated control.
  • a product whose LC 50 is less than 3 ⁇ M is considered to be cytotoxic
  • An endothelial cell detachment test was established in order to select the products on the basis of their "in vitro" activity.
  • This test for determining the detachment of endothelial cells is characterized in that the endothelial cells, seeded in plates whose bottom is covered with a binding agent preferably chosen from gelatin, fibronectin or vitronectin, after culture, are added with a medium containing the compound to be tested, then the cells are labeled with a fluorescent substance, the cells which have detached are washed away and the fluorescence of the remaining cells is counted with a fluorimeter.
  • This test consists in measuring the detachment of endothelial cells cultivated on substrates based on a binding agent preferably chosen from fibronectin, vitronectin or gelatin.
  • a binding agent preferably chosen from fibronectin, vitronectin or gelatin.
  • the culture medium is replaced by a medium containing the compound to be tested in the absence of serum.
  • the same preparation is prepared six times at three different concentrations (0.1, 0.3 and 0.6 ⁇ M) and six times the control without the addition of anti-vascular product.
  • the cells are labeled with calcein-AM (1.6 ⁇ g / ml) in culture medium supplemented with 0.1% BSA.
  • Cells which have become detached are removed by washing with the medium of culture containing 0.1% bovine serum albumin; 100 ⁇ l of medium are added to each well. The fluorescence of the remaining cells is counted using a fluorimeter. The data obtained are expressed relative to the control (untreated cells).
  • HDMEC cells Human Dermal Microvascular Endothelial Cells, Promocell, c-122102
  • ECGM-MV medium which contains 5% fetal calf serum, growth factors (EGF 10 ng / ml, hydrocortisone 1 ⁇ g / ml , 0.4% growth supplement with heparin) and antibiotics (amphotericin 50 ng / ml, gentamicin 50 ⁇ g / ml).
  • the HDMECs are seeded at 5,000 cells in 96-well bright-field plates (Costar) pre-coated with fibronectin (10 ⁇ g / ml) or vitronectin (1 ⁇ g / ml) or gelatin. Twenty four hours later, the culture medium is replaced by ECGM-MV 0.1% BSA medium containing the indicated products. The concentrations tested are 0.1-0.3 and 1 ⁇ M for each product. After two hours of treatment, the cells are labeled for one hour with calcein (1.6 ⁇ g / ml, Molecular Probes) in ECGM-MV 0.1% BSA medium.
  • the detached cells are then removed by washing with ECGM-MV 0.1% BSA medium; 100 ⁇ l of medium is added to each well.
  • the fluorescence of the cells which remain attached to the substrate of the well is counted using a fluorimeter, Spectrafluor Plus (Tecan, excitation 485 nm, and emission 535 nm). The data are the average of six different samples and are expressed as a percentage of the control (untreated cells).
  • a cell detachment effect greater than or equal to 15% is considered significant.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
EP04705102A 2003-01-28 2004-01-26 N-aryl-heteroaromatische produkte,zusammensetzungen, die diese enthalten, und deren verwendung Withdrawn EP1590329A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0300894 2003-01-28
FR0300894A FR2850379B1 (fr) 2003-01-28 2003-01-28 Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
FR0313086 2003-11-07
FR0313086 2003-11-07
PCT/FR2004/000168 WO2004078732A1 (fr) 2003-01-28 2004-01-26 Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
EP1590329A1 true EP1590329A1 (de) 2005-11-02

Family

ID=32963981

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04705102A Withdrawn EP1590329A1 (de) 2003-01-28 2004-01-26 N-aryl-heteroaromatische produkte,zusammensetzungen, die diese enthalten, und deren verwendung

Country Status (7)

Country Link
EP (1) EP1590329A1 (de)
JP (1) JP2006516656A (de)
AU (1) AU2004218260A1 (de)
BR (1) BRPI0407088A (de)
CA (1) CA2512243A1 (de)
MX (1) MXPA05008099A (de)
WO (1) WO2004078732A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2770832A4 (de) * 2011-10-24 2015-11-04 Avon Prod Inc Zusammensetzungen und verfahren zur stimulierung einer kollagensynthese in der haut

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525325A1 (en) * 2003-05-01 2004-11-18 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
MX2007008279A (es) * 2005-01-25 2008-02-15 Epix Delaware Inc Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6.
TW200800946A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Substituted piperazines as metabotropic glutamate receptor antagonists
WO2007119833A1 (ja) * 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited 含窒素複素環化合物
CN100444842C (zh) * 2006-11-30 2008-12-24 四川大学华西医院 N-芳基杂环族化合物的制药用途
KR20100095430A (ko) * 2007-11-02 2010-08-30 메틸진 인크. 히스톤 탈아세틸화효소의 저해물질
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
WO2010001258A2 (en) * 2008-06-30 2010-01-07 Centre National De La Recherche Scientifique Inhibition of tumour growth and metastases
NZ591896A (en) * 2008-08-29 2013-03-28 Treventis Corp Compositions and methods of treating amyloid disease
KR20130089232A (ko) 2010-06-15 2013-08-09 바이엘 인텔렉쳐 프로퍼티 게엠베하 안트라닐산 디아미드 유도체
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
CA2809624A1 (en) * 2010-09-08 2012-03-15 Bristol Myers Squibb Company Novel piperazine analogs as broad-spectrum influenza antivirals
ES2657942T3 (es) * 2012-05-18 2018-03-07 Vironova Influenza Ab Compuestos de metanotiona que tienen actividad antiviral
US9676734B2 (en) 2012-05-18 2017-06-13 Vironova Influenza Ab Compounds and methods
SMT202100031T1 (it) 2014-03-07 2021-03-15 Biocryst Pharm Inc Pirazoli trifluorometil-sostituiti come inibitori della callicreina plasmatica umana
EP3152198B1 (de) * 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radioaktiv markierte verbindungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61129129A (ja) * 1984-11-28 1986-06-17 Kureha Chem Ind Co Ltd 抗腫瘍剤
TW312694B (de) * 1994-09-26 1997-08-11 Daiichi Seiyaku Co
PL325341A1 (en) * 1996-06-29 1998-07-20 Samjin Pharmaceutical Co Derivatives od piperazine and method of obtaining them
DE10035908A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035928A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
JP2004536104A (ja) * 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
UA79286C2 (en) * 2002-06-29 2007-06-11 Zentaris Gmbh Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004078732A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2770832A4 (de) * 2011-10-24 2015-11-04 Avon Prod Inc Zusammensetzungen und verfahren zur stimulierung einer kollagensynthese in der haut

Also Published As

Publication number Publication date
BRPI0407088A (pt) 2006-01-24
WO2004078732B1 (fr) 2004-10-28
WO2004078732A1 (fr) 2004-09-16
AU2004218260A1 (en) 2004-09-16
CA2512243A1 (fr) 2004-09-16
JP2006516656A (ja) 2006-07-06
MXPA05008099A (es) 2005-09-21

Similar Documents

Publication Publication Date Title
EP1590329A1 (de) N-aryl-heteroaromatische produkte,zusammensetzungen, die diese enthalten, und deren verwendung
EP1641763B1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
CA2772718C (en) Compounds as tyrosine kinase modulators
JP5424256B2 (ja) アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途
FR2857966A1 (fr) Produits aryl-heteroaromatiques, compositions les contenant et utilisation
EP1641765A1 (de) Arylheteroaromatische produkte, zusammensetzungen, die diese enthalten, und verwendung davon
KR20170132934A (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP1765813A1 (de) Substituierte indazole, diese enthaltende zusammensetzungen, herstellung und verwendung
EA004805B1 (ru) 5-аминоиндено [1, 2-c]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
KR102537615B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CA3080116A1 (fr) Derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20050130989A1 (en) N-arylheteroaromatic products compositions containing them and use thereof
EP1633738A2 (de) Neue indolderivate, verfahren zu deren herstellung in form von medikamenten, pharmazeutische zusammensetzungen und insbesondere kdr-inhibitoren
JP4833832B2 (ja) ピラゾール化合物
EP1856043B1 (de) 1h-pyrrol-2-carbonsäureamide und imidazol-5-carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs
NZ527767A (en) Chromane derivatives, process for their preparation and their use as antitumor agents
EP1858898B1 (de) Hydrazinocarbonylthieno[2,3-c]pyrazole, herstellungsverfahren, zusammensetzungen die sie enthalten, und anwendung
WO2006003277A1 (fr) Produits biaryl aromatiques, compositions les contenant et utilisation comme medicaments
FR2960876A1 (fr) Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CA2139346A1 (fr) Derives de 2-imidazoline-5-ones et de 2-imidazoline-5-thiones fongicides
EP2108012A2 (de) Substituierte n-(4-cyan-1h-pyrazol-3-yl)methylamin-derivate, ihre herstellung und ihre therapeutische verwendung
FR2855825A1 (fr) Produits aryl-heteroaromatiques, compositions les contenant et utilisation
FR2827861A1 (fr) Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
CA2784153A1 (fr) Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP1878723B1 (de) N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamid-Derivate Antagonisten der CB1 Rezeptoren der Cannabinoide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SALVINO, JOSEPH M.

Inventor name: MAILLIET, PATRICK

Inventor name: TIRABOSCHI, GILLES

Inventor name: THOMPSON, FABIENNE

Inventor name: LE-BRUN, ALAIN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SALVINO, JOSEPH M.

Inventor name: MAILLIET, PATRICK

Inventor name: TIRABOSCHI, GILLES

Inventor name: THOMPSON, FABIENNE

Inventor name: LE-BRUN, ALAIN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20061212